Details for New Drug Application (NDA): 208564
✉ Email this page to a colleague
NDA 208564 describes IMVEXXY, which is a drug marketed by Mayne Pharma and is included in one NDA. There are twenty patents protecting this drug. Additional details are available on the IMVEXXY profile page.
The generic ingredient in IMVEXXY is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.
The generic ingredient in IMVEXXY is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.
Summary for 208564
| Tradename: | IMVEXXY |
| Applicant: | Mayne Pharma |
| Ingredient: | estradiol |
| Patents: | 20 |
Medical Subject Heading (MeSH) Categories for 208564
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INSERT;VAGINAL | Strength | 0.004MG | ||||
| Approval Date: | May 29, 2018 | TE: | AB | RLD: | Yes | ||||
| Patent: | 10,258,630 | Patent Expiration: | Nov 21, 2032 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY | ||||||||
| Patent: | 10,258,630 | Patent Expiration: | Nov 21, 2032 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF DYSPAREUNIA | ||||||||
| Patent: | 10,398,708 | Patent Expiration: | Nov 21, 2032 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY | ||||||||
Complete Access Available with Subscription
